The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

Gerard Milano; Federico Innocenti; Joseph Ciccolini

doi:10.1016/j.tranon.2020.100952

The association between adverse events and outcome under checkpoint inhibitors: Where is the deal?

Transl Oncol. 2021 Jan;14(1):100952. doi: 10.1016/j.tranon.2020.100952. Epub 2020 Nov 28.

Authors

Gerard Milano¹, Federico Innocenti², Joseph Ciccolini³

Affiliations

¹ UNS EA 7497 Nice University, Centre Antoine Lacassagne, 33 avenue de Valombrose, 06189 Cedex 2, France. Electronic address: gerard.milano@nice.unicancer.fr.
² UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA.
³ SMARTc School of Pharmacology, Marseille, France.

Abstract

Recent reports have put into evidence the possibility of a link between immune-related adverse events (IRAEs) and treatment outcome, patients drawing a benefit from treatment being also exposed to the risk to develop toxicity. A still unanswered question remains the biological origin(s) which can sustain and explain such a relationship. The purpose of this review paper is to lay out different potential contributions which can help to understand the IRAEs-outcome link and to propose clinical perspectives taking advantage of this association. In this respect, pharmacokinetics aspects, immunological and immunogenetics implications have been taken into consideration.

Keywords: Checkpoint inhibitors; Immune-related adverse events; Immunotherapy; Treatment efficacy.

Publication types

Review